Pharmacological targeting of the PLK1‐MYC‐CDC7 axis enhanced the efficacy of oxaliplatin, which provided potential clinical advantage in using PLK1 or CDC7 inhibitor in combination with chemotherapy regimens in treatment of CRC patients. Here, PLK1 is linked to colorectal carcinoma.